We are live on ! Find out more
MNPR icon

Monopar Therapeutics

9 hedge funds and large institutions have $964K invested in Monopar Therapeutics in 2021 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 2

0.02% more ownership

Funds ownership: 0.3%0.32% (+0.02%)

10% less funds holding

Funds holding: 109 (-1)

13% less capital invested

Capital invested by funds: $1.1M → $964K (-$140K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

Holders
9
Holders Change
-1
Holders Change %
-10%
% of All Funds
0.16%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
3
Reduced
2
Closed
1
Calls
Puts
Net Calls
Net Calls Change

MNPR Hedge Fund Activity: Q3 2021 in Review

9 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Monopar Therapeutics (MNPR) for Q3 2021, worth a combined $964K — down 13% from $1.1M a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of MNPR and 0 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 3 added.

The largest buyer was Geode Capital Management, adding an estimated $53.9K. The largest seller was BlackRock, cutting an estimated $5.59K.

  • 9 institutional investors held Monopar Therapeutics (MNPR) as of Q3 2021, down from 10 in Q2 2021.
  • Funds reported $964K of Monopar Therapeutics stock for Q3 2021, down 13% quarter-over-quarter.
  • 0 funds opened new Monopar Therapeutics positions in Q3 2021 and 1 closed out, a net change of -1 holder.
  • The largest Monopar Therapeutics buyer in Q3 2021 was Geode Capital Management, an estimated $53.9K added.
  • The largest Monopar Therapeutics seller in Q3 2021 was BlackRock, an estimated $5.59K sold.

Based on aggregated 13F filings for Q3 2021.